BACKGROUND
Current viral load tests for human immunodeficiency virus (HIV) can only be performed in laboratory environments, require highly trained operators and expensive equipment, and have a turnaround time of several hours to days. The Liat HIV Quant Assay proves that such nucleic acid testing can be performed rapidly and easily, allowing application at the point of care.
METHODS
The Liat Analyzer automates the entire assay, including sample preparation, amplification, and detection, in a self-contained and closed-tube system. Dynamic range, limit of detection, and subtype specificity were evaluated. Clinical samples were tested retrospectively to correlate the result of this assay with those of commercial HIV load assays.
RESULTS
The Liat assay demonstrated linearity of >6 logs (R(2), 0.98) and a limit of detection of 57 copies/mL. HIV-1 group M (clades A-H), group O, and HIV-2 were detected. Testing of clinical samples showed a high degree of concordance between the copy numbers detected by the Liat assay and those detected by the Siemens and Roche assays (92.0% and 88% correlation coefficient of the log copy number, respectively). The time from sample collection to result was 88 min.
CONCLUSIONS
Results suggest that the Liat HIV Quant Assay has performance equivalent to that of commercial HIV load assays and significantly reduces assay time, simplifies test operation, and provides biocontainment to allow operation in nonlaboratory settings.
[1]
S. Hammer,et al.
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
,
1998,
The Journal of infectious diseases.
[2]
J. Hackett,et al.
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples.
,
2007,
Journal of virological methods.
[3]
J. Margolick,et al.
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users
,
2004,
AIDS.
[4]
M. Elashoff,et al.
The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.
,
1999,
AIDS.
[5]
Wolfram Schumacher,et al.
Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system.
,
2007,
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[6]
John W. Mellors,et al.
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
,
1996,
Science.
[7]
James Curran,et al.
Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach
,
2005
.